• linkedin
  • Increase Font
  • Sharebar

    Data demonstrate real-world benefits of fluocinolone acetonide implant

    Findings could spell change in way chronic diabetic macular oedema is treated in UK

     


    References

    1.     Iluvien, Summary of Product Characteristics.

    2.     National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). NICE technology appraisal guidance 301, 2013. Available at: www.nice.org.uk/guidance/ta301. [Accessed October 2017]

    3.     Bailey C, et al. Real-world experience with 0.2μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 21st July 2017. [Epub ahead of print]. Available at: http://www.nature.com/eye/journal/vaop/ncurrent/full/eye2017125a.html?fo...

    4.     National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. Technology appraisal guidance [TA346], 2015. Available at: https://www.nice.org.uk/guidance/ta346/chapter/1-Guidance [Accessed October 2017]

    5.     National Institute for Health and Care Excellence. Ranibizumab for treating diabetic macular oedema. Technology appraisal guidance [TA274], 2013. Available at: https://www.nice.org.uk/guidance/ta274/chapter/1-Guidance

    6.     Campochiaro PA, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125-2132.

    7.     Quhill F, Beiderbeck A. Cost advantage of fluocinolone acetonide implant (ILUVIEN) versus ranibizumab in the treatment of chronic diabetic macular oedema. Global & Regional Health Technology Assessment. 2017;4(1):e155-e164.

     

    Dr Clare Bailey, MD FRCP FRCOphth

    E:[email protected]

    Dr Bailey is a consultant ophthalmologist at Bristol Eye Hospital, specialising in retinal disorders. She has been the clinical director of the retinal treatment and research unit since 2012, undertaking clinical research into retinal disorders, particularly age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. She is the NIHR West of England lead for ophthalmology. 

    Dr Bailey participates in occasional advisory board meetings for Bayer, Novartis, Alimera Sciences, Roche and Allergan. Bristol Eye Hospital has undertaken clinical research funded by Bayer, Allergan, Roche, Novartis and Alimera Sciences.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';